On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran, significantly reduces melanoma recurrence and spread in a phase 3 trial. Combining intismeran with Merck’s Keytruda showed notable improvements in patient outcomes, marking a pivotal… Read More »New mRNA vaccine cuts recurrence and spread of melanoma
Merck settled recent Gardasil lawsuits for approximately $50 million, despite winning prior litigation, primarily to avoid high litigation costs. The settlement does not validate the plaintiffs’ claims, as studies show no link between Gardasil and their alleged conditions. The Vaccine… Read More »Explanation of the settlement of Gardasil lawsuits by Merck
A recent study reveals that an individualized mRNA vaccine for surgically resected melanoma, developed by Moderna and Merck, significantly reduces recurrence and distant spread risks over a five-year period. When combined with Keytruda, it boosts survival rates, showcasing the potential… Read More »Melanoma mRNA vaccine halves risk of recurrence, metastasis
HHS Secretary RFK Jr. has canceled over $500 million in mRNA vaccine funding, jeopardizing future vaccine development amidst ongoing health crises like bird flu. His anti-mRNA stance contradicts scientific evidence, risking delays in vital research. This decision threatens public health… Read More »RFK Jr cancels $500 million funding of mRNA vaccine research
Merck and Moderna’s Phase 3 trials for the personalized mRNA cancer vaccine V940 aim to evaluate its effectiveness with Keytruda in non-small cell lung cancer patients post-surgery. This mRNA treatment is tailored to individual antigens to enhance immune response, potentially… Read More »Merck and Moderna lung cancer mRNA vaccine in phase 3 trials
In an April 2025 interview, HHS Secretary Robert F. Kennedy Jr. claimed the mumps component of the MMR vaccine is ineffective, promoting anti-vaccine sentiment despite extensive evidence supporting vaccine safety and efficacy. The mumps vaccine has significantly reduced disease incidence,… Read More »RFK Jr thinks the mumps vaccine is ineffective — wrong again
The article discusses a recent federal court ruling favoring Merck in Gardasil litigation, concluding that plaintiffs failed to prove a causal link between the HPV vaccine and conditions like POTS and POI. The court emphasized the lack of substantial evidence… Read More »Court grants summary judgment in Gardasil litigation
Robert F. Kennedy Jr. (RFK Jr.) has a history of promoting false claims about vaccines, particularly the HPV vaccine. His misinformation undermines public health by questioning vaccine safety without scientific basis. Accurate data shows the HPV vaccine is safe and… Read More »RFK Jr pushes false claims about HPV cancer-prevention vaccine
A phase 3 clinical trial revealed that the 9-valent HPV vaccine, Gardasil® 9, effectively prevents anogenital HPV infections in Japanese males. Despite previous concerns from Japan’s health ministry, the vaccine is proven safe and effective in preventing various cancers, supporting… Read More »9-valent HPV vaccine is effective in young Japanese males
The Third Circuit Court of Appeals upheld the dismissal of a lawsuit against Merck, which alleged fraud related to the mumps component of its MMR vaccine. The court found no material fraud affecting the CDC’s purchasing decision. Despite claims of… Read More »Court of Appeals upholds dismissal of Merck MMR vaccine lawsuit